All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 4, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Flag of India

Indian pharma sector needs to learn from its competitors: report

Dec. 3, 2019
By T.V. Padma
No Comments
NEW DELHI, India – While India is still an attractive prospect for investment in biotechnology, the country needs to learn from the successful examples of other countries, including its Asian biotech competitors, according to a new report.
Read More
Tuberculosis

In India, government steps up efforts to develop more TB testing and treatment

Dec. 3, 2019
By T.V. Padma
No Comments
HYDERABAD – India, home to a quarter of the global tuberculosis (TB) cases, plans to enhance its capacity to fight TB drug resistance and bolster susceptibility testing under a new initiative launched by the Geneva-based nonprofit Foundation for Innovative New Diagnostics (FIND).
Read More
Stock chart, upward arrow
IPO class of 2019

Biopharma stocks up 26% on average since debut with Karuna as top performer

Dec. 2, 2019
By Karen Carey
No Comments
With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and pain.
Read More
A quick look back at top stories

Blockbuster deals capture attention heading into the Thanksgiving holiday

Nov. 27, 2019
No Comments
A quick look back at top stories.
Read More

Money raised by biopharma: 2019 vs. 2018

Nov. 27, 2019
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.
Read More

Biopharma money raised: Jan. 1-Nov. 26, 2019

Nov. 27, 2019
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: August 2019

Nov. 27, 2019
No Comments
Deals between biopharma companies and government or nonprofit entities in August 2019.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: September 2019

Nov. 27, 2019
No Comments
Deals between biopharma companies and government or nonprofit entities in September 2019.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: October 2019

Nov. 27, 2019
No Comments
Deals between biopharma companies and government or nonprofit entities in October 2019.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: November 2019

Nov. 27, 2019
No Comments
Deals between biopharma companies and government or nonprofit entities in November 2019.
Read More
Previous 1 2 … 148 149 150 151 152 153 154 155 156 … 163 164 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 2, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • EU flag, pills, syringe

    Otsuka’s schizophrenia drug filing U-turn amongst latest CHMP announcements

    BioWorld
    Otsuka Pharmaceutical Co. Ltd. has gone back on efforts to get its medicine, Asimtufii (aripiprazole), a long-acting maintenance treatment for schizophrenia,...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing